What’s Happening With Regeneron Pharmaceuticals Stock On Monday?

All NewsSeptember 8, 2025

Regeneron’s Phase 3 trials for cat and birch allergies show significant symptom relief and strong safety results, paving the way for future development.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent